COMPANY PROFILE

Apmonia Therapeutics

Explore full profile

Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies

Reims, FranceFounded 2019Biotech & Life Sciences

Valuation $25–50M Last recorded · 2026

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Apmonia Therapeutics

Apmonia Therapeutics is a pharmaceutical startup that specializes in the development of innovative cancer therapies. The company's team comprises of professionals from the fields of science, development, and business, all working together to transform groundbreaking scientific discoveries into practical medical solutions. Their primary clients are individuals suffering from various types of cancer, particularly those with high unmet medical needs.

Read full description

The company operates in the pharmaceutical industry, specifically in the immuno-oncology sector. Immuno-oncology refers to the science of using the body's immune system to fight cancer. Apmonia Therapeutics' research and development platform is based on extracellular matrix biology, molecular modeling, and in-house screening processes. In simpler terms, they study how cells interact with their surroundings, model these interactions on a molecular level, and screen potential drug candidates in-house.

Their business model revolves around the development and commercialization of these drug candidates. Their lead program, AP-01, is a drug that targets TSP-1, a protein involved in tumor growth. By targeting this protein, the drug aims to inhibit tumor growth and provide a new treatment option for cancer patients.

The company generates revenue through the sale of its pharmaceutical products once they have demonstrated clinical efficacy. As a startup, they may also rely on funding from investors and grants for research and development.

In conclusion, Apmonia Therapeutics is a promising startup in the pharmaceutical industry, with a focus on innovative cancer therapies. Their unique approach to drug development, combined with their commitment to addressing unmet medical needs, positions them as a potential leader in the immuno-oncology sector.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Reims, France
Employees: 20
Open positions: None listed
Dealroom signal: 76.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, EIC, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe, observatoire industrial tech, proteomics
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Feb 2026	$11M	$44M	Capital Grand Est · Business Angels Marne Ardennes · Capital Cell · Angels Santé	↗
GRANT✓Other financing	Apr 2024	$3M	—	Région Grand Est · French Ministry of Economics and Finance · France 2030	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Apmonia Therapeutics website traffic

Latest recorded traffic for Apmonia Therapeutics is 410 monthly website visits, up 20.6% over the last three months. Apmonia Therapeutics's team grew 11.1% over the past year.

Latest monthly visits410 3-month web change+20.6% 1-year team growth+11.1%

Monthly website visitsOct 2020–Mar 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational	29	$18M	$53M
STStimunityTurn cancer immunotherapies active in most patient	Paris, France	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
ERErVimmuneOff-the-shelf cancer vaccines targeting unconventional tumor antigens.	Lyon, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational
EVEverZomA key asset to the future health of an ageing population	Paris, France	Operational